NASDAQ:CTRV ContraVir Pharmaceuticals (CTRV) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free CTRV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.22▼$1.6050-Day Range$2.53▼$3.5852-Week Range$3.52▼$91.00Volume322,305 shsAverage Volume432,822 shsMarket Capitalization$1.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get ContraVir Pharmaceuticals alerts: Email Address Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About ContraVir Pharmaceuticals Stock (NASDAQ:CTRV)ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.Read More Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy CTRV Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive CTRV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraVir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2016Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:CTRV CUSIPN/A CIK1583771 Webwww.contravir.com Phone732-902-4000FaxN/AEmployees14Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,450,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-4,810.77% Return on Assets-130.14% Debt Debt-to-Equity RatioN/A Current Ratio0.55 Quick Ratio0.55 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.76Miscellaneous Outstanding Shares800,000Free FloatN/AMarket Cap$1.13 million OptionableNot Optionable Beta1.16 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Robert T. Foster BSc (Pharm) (Age 61)Pharm.D., Ph.D., CEO, Pres, Chief Scientific Officer & Director Dr. John Z. Sullivan-Bolyai (Age 71)Part-Time Consultant Mr. John T. Cavan (Age 61)Chief Financial Officer Sharen PyatetskayaDirector of Investor RelationsKey CompetitorsGRI BioNASDAQ:GRINeuBase TherapeuticsNASDAQ:NBSEGalmed PharmaceuticalsNASDAQ:GLMDPanbela TherapeuticsNASDAQ:PBLADermata TherapeuticsNASDAQ:DRMAView All Competitors CTRV Stock Analysis - Frequently Asked Questions How were ContraVir Pharmaceuticals' earnings last quarter? ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) issued its quarterly earnings data on Friday, May, 13th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.80) by $0.68. When did ContraVir Pharmaceuticals' stock split? ContraVir Pharmaceuticals shares reverse split before market open on Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of ContraVir Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ContraVir Pharmaceuticals investors own include Ayala Pharmaceuticals (ADXS), Alliqua Biomedical (ALQA), Synergy Pharmaceuticals (SGYP), Palatin Technologies (PTN), LadRx (CYTR), Madrigal Pharmaceuticals (MDGL), Biopharmx (BPMX), Heat Biologics (HTBX) and Ritter Pharmaceuticals (RTTR). This page (NASDAQ:CTRV) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
